ArticleBMC ophthalmology2026
Type 4 macular neovascularization in a consecutive age-related macular degeneration cohort: detected prevalence and multimodal imaging findings.
Article in BMC ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo determine the detected prevalence of type 4 macular neovascularization (MNV) within a retrospectively screened age-related macular degeneration (AMD) cohort and to characterize its clinical, structural, and angiographic features.
methodsThis single-center retrospective cohort study included 4658 structural OCT examinations from 962 eyes of 500 patients with age-related macular degeneration (AMD). Eyes with structural OCT findings suggestive of type 4 MNV underwent multimodal evaluation via structural OCT and available OCT angiography (OCTA). Cases were categorized as definite, probable, or non-type 4 MNV according to predefined multimodal imaging criteria. Detected prevalence within the screened cohort was calculated at the patient and eye levels with exact 95% Clopper-Pearson confidence intervals (CIs).
resultsThe detected prevalence of definite type 4 MNV within the entire consecutive AMD cohort was 2.00% (95% confidence interval [CI], 0.96-3.65%) at the patient level and 1.04% (95% CI, 0.50-1.90%) at the eye level. The hyperreflective oblique band (HOB), subretinal hyperreflective material (SHRM), and ellipsoid zone (EZ) loss were present in all the definite cases. Central posterior hyaloid fibrosis (CPHF) was observed in half of the definite cases, whereas the remaining eyes exhibited posterior hyaloid central hyperreflectivity (PHCH). By definition, the OCTA criterion of a continuous flow signal extending from the inner choroid to the preretinal space was fulfilled in all definite cases. During follow-up, HOB, CPHF, and PHCH remained stable, whereas exudative activity varied.
conclusionsWithin this consecutive AMD cohort, type 4 MNV was an uncommon phenotype characterized by recognizable structural and angiographic features. Structural OCT was used to identify eyes suspicious for type 4 MNV, whereas designation as definite type 4 MNV required demonstration on OCTA of the continuous flow signal specified in the predefined criteria. Our findings further characterize the clinical, structural, and angiographic features of type 4 MNV in this retrospective cohort.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.